RxDoctor Payments Data

Nancy Baron-Welch

Women's Health · Newark, DENPI 1245514140

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,877in general payments, 2019–2025

Across 196 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$569
  • Astellas Pharma US Inc$457
  • Evofem Biosciences, Inc.$335
  • AbbVie$302
  • Exeltis, USA Inc.$214
  • Myovant Sciences Inc.$194
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,67895%
  • Education$2005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,877 in reported general payments places this provider in the 95th percentile of 29 women's health providers in Delaware.

See all women's health providers in Delaware

Medicare billing

Part B allowed, 2024
$5,186
Medicare patients
103
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol23$1,504
Alendronate Sodium15$187

Paid to pharmacies, not to this prescriber.

Other women's health in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →